Teva Pharmaceutical Industries Investor Presentation — February 2020

Document content

Teva Pharmaceutical Industries Ltd.

Fourth Quarter 2019 Results

February 12, 2020 Cautionary Note Regarding Forward-Looking Statements

This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, which are based on management’s current beliefs and expectations and are subject to

substantial risks and uncertainties, both known and unknown, that could cause our future results, performance or achievements to differ significantly from that expressed or implied by such forward-looking statements.

Important factors that could cause or contribute to such differences include risks relating to:

•our ability to successfully compete in the marketplace, including: that we are substantially dependent on our generic products; c onsolidation of our customer base and commercial alliances among our customers; the

increase in the number of competitors targeting generic opportunities and seeking U.S. market exclusivity for generic versions o f significant products; competition for our specialty products, especially COPAXONE®, our

leading medicine, which faces competition from existing and potential additional generic versions, competing glatiramer acetate products and orally -administered alternatives; the uncertainty of commercial success of

AJOVY® or AUSTEDO®; competition from companies with greater resources and capabilities; delays in launches of new products and our ability to achi eve expected results from investments in our product pipeline; ability

to develop and commercialize biopharmaceutical products; efforts of pharmaceutical companies to limit the use of generics, inclu ding through legislation and regulations and the effectiveness of our patents and other

measures to protect our intellectual property rights ;

•our substantial indebtedness, which may limit our ability to incur additional indebtedness, engage in additional transactions or make new investments, may result in a further downgrade of our credit ratings; and our

inability to raise debt or borrow funds in amounts or on terms that are favorable to us ;

•our business and operations in general, including: implementation of our restructuring plan announced in December 2017; our ability to attract, hire and retain highly skilled personnel; our ability to develop and

commercialize additional pharmaceutical products; compliance with anti -corruption, sanctions and trade control laws; manufacturi ng or quality control problems; interruptions in our supply chain; disruptions of information

technology systems; breaches of our data security; variations in intellectual property laws; challenges associated with conducti ng business globally, including adverse effects of political or economic instability, major